Race affects opioid selection for cancer pain

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

Salimah H. Meghani, Ph.D., R.N., from the University of Pennsylvania in Philadelphia, and colleagues recruited 182 patients from clinics within a single health system. All participants reported the presence of cancer-related pain plus a prescription for morphine or oxycodone. The abbreviated Modification of Diet in Renal Disease formula was used to estimate kidney function.

The researchers found that the severity of analgesic-related adverse effects was greater for patients with (CKD) who received morphine versus oxycodone (P = 0.010). Compared with white patients, African-American patients had 71 percent lower odds of receiving a prescription of oxycodone (P < 0.001), when controlling for health insurance type. The effect of private insurance was no longer significant on limiting the analysis to patients with CKD, but race remained a significant predictor of the prescribed opioid selection. In the presence of CKD, race was a strong predictor for adverse effect severity, and this association was partially mediated by the type of opioid selection.

"Reducing racial disparities in the type of opioid prescription and understanding mechanisms of disproportionate opioid-related in African-American patients might decrease the clinical disparities in cancer pain outcomes," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Added corticosteroid deemed ineffective for cancer pain

date Jul 16, 2014

(HealthDay)—The addition of methylprednisolone (MP) to opioid therapy does not appear to increase the analgesic effect for cancer pain, according to research published online July 7 in the Journal of Cl ...

Recommended for you

Teva buying Auspex for $3.2 billion

date Mar 30, 2015

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Oral hepatitis B vaccine could become a reality

date Mar 30, 2015

In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.